Individualized therapy for primary lung cancer: BIM polymorphism as a stratification factor
| Project/Area Number |
15K09195
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KABURAKI kyouhei 東邦大学, 医学部, 助教 (00439944)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | BIM遺伝子多型 / PD-L1 / BIMγ / 原発性肺癌 / EGFR遺伝子変異 / BIM-γ / EGFRチロシンキナーゼ阻害薬 / 非小細胞癌 / 非小細胞肺癌 |
|---|
| Outline of Final Research Achievements |
Expression of BIM protein in primary lung tumors in EGFR-mutated lung adenocarcinoma did not correlate with presence of BIM polymorphism, which was noted in about half of patients. In all patients with BIM polymorphism, BIMγ was expressed in the tumor area or non-tumor area. Moreover, the frequency was significantly higher, and the relative quantification value was nonsignificantly higher, than in patients without BIM polymorphism. Progression-free survival for gefitinib was significantly shorter in patients with positive BIMγ expression, which suggests that BIMγ expression is associated with poor prognosis in patients with EGFR-mutated lung adenocarcinoma receiving gefitinib. In addition, BIM expression in the tumor area significantly positively correlated with PD-L1 expression.
|
Report
(4 results)
Research Products
(8 results)
-
[Journal Article] PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma2018
Author(s)
Kazutoshi Isobe, Atsushi Kakimoto, Tetuo Mikami, Kyohei Kaburaki, Hiroshi Kobayashi, Takahiro Yoshizawa , Yuta Nakano, Takashi Makino3, Hajime Otsuka, Go Sano, Keishi Sugino, Susumu Sakamoto, Yujiro Takai, Naobumi Tochigi, Akira Iyoda, Sakae Homma
-
Journal Title
Oncology Report
Volume: 印刷中
Related Report
Peer Reviewed / Open Access
-
[Journal Article] A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.2017
Author(s)
Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT.
-
Journal Title
Oncotarget
Volume: 印刷中
Issue: 25
Pages: 41474-41486
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.2016
Author(s)
Isobe K, Kakimoto A, Mikami T, Kaburaki K, Kobayashi H, Yoshizawa T, Makino T, Otsuka H, Sano GO, Sugino K, Sakamoto S, Takai Y, Tochigi N, Iyoda A, Homma S.
-
Journal Title
Cancer Genomics Proteomics.
Volume: 13
Pages: 475-482
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
